Literature DB >> 12719706

Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system.

Lars H Lund1, Karolina Andersson, Bartek Zuber, Anneli Karlsson, Gunnel Engström, Jorma Hinkula, Britta Wahren, Gösta Winberg.   

Abstract

Carcinoembryonic antigen (CEA, CEACAM5) is expressed on several human carcinomas including colon cancer. CEA contains signal peptides that target the protein through the endoplasmic reticulum and to the cell membrane. We constructed a plasmid DNA vaccine encoding a truncated CEA (deltaCEA), devoid of its signal peptides, and demonstrated that it was retained inside the cell, while full-length CEA (wtCEA) was expressed on the membrane. We hypothesized that intracellular retention of deltaCEA would enhance MHC class I presentation of CEA peptides, thus favoring cellular immune responses. In addition, a promiscuous T-helper epitope (Q830-L844 of tetanus toxoid) was fused to the N-terminal of the truncated CEA gene (tetdeltaCEA). C57BL/6 mice immunized with DNA encoding wtCEA or tetdeltaCEA developed both humoral and cellular immune responses to CEA. SCID mice transplanted with spleen cells from tetdeltaCEA but not wtCEA-immunized C57BL/6 mice showed strong suppression of tumor growth after inoculation of human CEA-expressing colon carcinoma cells. Immune spleen cell populations depleted for either B, T or both B and T cells were active, indicating that effector cells might also reside in other populations. The present approach to manipulating antigen presentation may open new possibilities for immunotherapy against colon and other CEA-secreting carcinomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719706     DOI: 10.1038/sj.cgt.7700574

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  5 in total

1.  scFv6.C4 DNA vaccine with fragment C of Tetanus toxin increases protective immunity against CEA-expressing tumor.

Authors:  Bianca Ferrarini Zanetti; Camila Pontes Ferreira; José Ronnie Carvalho de Vasconcelos; Sang Won Han
Journal:  Gene Ther       Date:  2019-02-15       Impact factor: 5.250

2.  Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma.

Authors:  Sandra Iurescia; Daniela Fioretti; Pasquale Pierimarchi; Emanuela Signori; Manuela Zonfrillo; Giancarlo Tonon; Vito M Fazio; Monica Rinaldi
Journal:  J Biomed Biotechnol       Date:  2010-04-27

3.  Antiidiotypic DNA vaccination induces serum bactericidal activity and protection against group B meningococci.

Authors:  Concetta Beninati; Angelina Midiri; Giuseppe Mancuso; Carmelo Biondo; Milena Arigò; Elisabetta Gerace; Salvatore Papasergi; Maria Gambuzza; Mauro Boretti; Walter Magliani; Stefania Conti; Luciano Polonelli; Giuseppe Teti
Journal:  J Exp Med       Date:  2006-01-03       Impact factor: 14.307

4.  Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif.

Authors:  Luis M Molinos-Albert; Eneritz Bilbao; Luis Agulló; Silvia Marfil; Elisabet García; Maria Luisa Rodríguez de la Concepción; Nuria Izquierdo-Useros; Cristina Vilaplana; Jon A Nieto-Garai; F-Xabier Contreras; Martin Floor; Pere J Cardona; Javier Martinez-Picado; Bonaventura Clotet; Jordi Villà-Freixa; Maier Lorizate; Jorge Carrillo; Julià Blanco
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

5.  Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirus-associated cancer.

Authors:  Chao-Chih Wu; Fang-Cih Wu; Yun-Tin Hsu; Yu-Chia Hsiao; Yuh-Cheng Yang; C Allen Chang; Chih-Long Chang
Journal:  Oncotarget       Date:  2017-05-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.